Corresponding author:
Dr. Mohammad Hassan Hablolvarid, Veterinary Pathologist, Department of Animal Pathology and Epidemiology, Razi vaccine and serum research institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj-Iran.
hablolvarid@yahoo.com
h.hablolvarid@rvsri.ac.ir
  1. Bell, T. J., Brand, O. J., Morgan, D. J, et al (2018). Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis. Matrix Biol . 80 , 14–28.
  2. Cronstein, B. N., Molad, Y., Reibman, J., et al (1995). Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest .96 (2), 994–1002.
  3. Finkelstein, T., Aks, S., Hutson, J. R., Juurlink, D. R, et al (2010). Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila) . 48 (5), 407-14. doi: 10.3109/15563650.2010.495348.
  4. González-Gay, M. A., Mayo, J., Castañeda, S., Cifrián, J. M and Hernández-Rodríguez, J (2020). Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces, Expert Opinion on Biological Therapy ,20 (7), 717-723 doi: 10.1080/14712598.2020.1770222
  5. Gu, Y., Hsu, A. C., Pang, Z., et al (2019). Role of the innate cytokine storm induced by the influenza A virus. Viral Immunol .32 (6), 244–251. doi:10.1089/ vim.2019.0032.
  6. Hallgren, R., Samuelsson, T., Laurent, T.C., and Modig, J (1989). Accumulation of hyaluronan (hyaluronic acid) in the lung in adult respiratory distress syndrome. Am Rev Respir Dis . 139 , 682–7. doi: org/10.1164/ajrccm/139.3.682
  7. Han, H., Ma, Q., Li, C., Liu, R., et al (2020). Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerging Microbes & Infections ,9 (1), 1123-1130. doi: 10.1080/22221751.2020.1770129
  8. Lauer, M. E., Dweik, R. A., Garantziotis, S., and Aronica, M. A (2015). The rise and fall of hyaluronan in respiratory diseases.Int J Cell Biol . 2015: 712507. doi: org/10.1155/2015/712507
  9. Leung, Y. Y., Hui, L. L. Y., and Kraus, V. B (2015). Colchicine — update on mechanisms of action and therapeutic uses.Semin Arthritis Rheum . 45 (3), 341–350. doi:10.1016/j.semarthrit.2015.06.013.
  10. Li, B., Feng, F., Yang, G., Liu, A., et al (2020). Immunoglobulin G/M and Cytokines Detections in Continuous Sera from Patients with Novel Coronaviruses (2019-nCoV) Infection. Available at: SSRN: https://ssrn.com/abstract=3543609 or http://dx.doi.org/10.2139/ssrn.3543609
  11. Liu, Y., Zhang, C., Huang, F., Yang, Y., Wang, F., et al (2020). Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury. National Science Review . 7 (6), 1003–1011, doi.org/10.1093/nsr/nwaa037
  12. Marietta, M., Ageno, W., Artoni, A., De Candia, E., et al (2020). COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfusion = Trasfusione del Sangue. 18 (3), 167-169. doi: 10.2450/2020.0083-20
  13. Marques-da-Silva, C., Chaves, M. M., Castro, N. G., et al (2011). Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br J Pharmacol . 163 (5), 912–926.
  14. Martinon, F., Pétrilli, V., Mayor, A., et al (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature .440 (7081), 237–241.
  15. Pascual, E., and Castellano, J. A (1992). Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals. J Rheumatol .19, 600–603.
  16. Rahmati, M., and Moosavi, MA (2020). Cytokine-targeted therapy in severely ill COVID-19 patients: Options and Cautions. EJMO .4 (2): 179-181. doi: 10.14744/ejmo.2020.72142
  17. Ren, L. L., Wang, Y. M., Wu, Z. Q., et al (2020). Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J . 133 (9), 1015-1024. doi:10.1097/CM9.0000000000000722
  18. Ruan, Q., Yang, K., Wang, W., Jiang, L., Song, J (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med .46 (5), 846-848. doi: 10.1007/s00134-020-05991-x.
  19. Russell, C. D., Millar, J. E., and Baillie, J. K (2020). Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet . 395 (10223), 473-75. doi: 10.1016/S0140-6736(20)30317-2.
  20. Shi, Y., Wang, Y., Shao, C., et al (2020). COVID-19 infection: the perspectives on immune responses. Cell Death & Differentiation . 27 , 1451–1454. doi:org/10.1038/s41418-020-0530-3
  21. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. [Epub ahead of print]. doi: org/10.1001/jama.2020.1585.
  22. Xu, Z., Shi, L., Wang, Y., et al (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome.Lancet Respir Med . 8 (4), 420-422. doi: 10.1016/S2213-2600(20)30076X
  23. Zhang, C., Wu, Z., Li, J. W., Zhao, H., Wang, G. Q (2020). The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. International Journal of Antimicrobial Agents .55 (5), 05954 doi: 10.1016/j.ijantimicag.2020.105954
  24. Zhou, Y., Fu, B., Zheng, X., Wang, D., Zhao, C., Sun, R., et al (2020). Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. National Science Review . 7 (6), 998–1002, doi.org/10.1093/nsr/nwaa041